398 related articles for article (PubMed ID: 16258089)
1. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.
Smith MR; Lee WC; Brandman J; Wang Q; Botteman M; Pashos CL
J Clin Oncol; 2005 Nov; 23(31):7897-903. PubMed ID: 16258089
[TBL] [Abstract][Full Text] [Related]
2. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.
Smith MR; Boyce SP; Moyneur E; Duh MS; Raut MK; Brandman J
J Urol; 2006 Jan; 175(1):136-9; discussion 139. PubMed ID: 16406890
[TBL] [Abstract][Full Text] [Related]
3. Fracture risk in Danish men with prostate cancer: a nationwide register study.
Abrahamsen B; Nielsen MF; Eskildsen P; Andersen JT; Walter S; Brixen K
BJU Int; 2007 Oct; 100(4):749-54. PubMed ID: 17822455
[TBL] [Abstract][Full Text] [Related]
4. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden.
Thorstenson A; Bratt O; Akre O; Hellborg H; Holmberg L; Lambe M; Bill-Axelson A; Stattin P; Adolfsson J
Eur J Cancer; 2012 Jul; 48(11):1672-81. PubMed ID: 22386317
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk factors for low trauma fractures in men with prostate cancer.
Ahlborg HG; Nguyen ND; Center JR; Eisman JA; Nguyen TV
Bone; 2008 Sep; 43(3):556-60. PubMed ID: 18585119
[TBL] [Abstract][Full Text] [Related]
6. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
[TBL] [Abstract][Full Text] [Related]
7. Therapy Insight: osteoporosis during hormone therapy for prostate cancer.
Smith MR
Nat Clin Pract Urol; 2005 Dec; 2(12):608-15; quiz 628. PubMed ID: 16474548
[TBL] [Abstract][Full Text] [Related]
8. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
Krupski TL; Smith MR; Lee WC; Pashos CL; Brandman J; Wang Q; Botteman M; Litwin MS
Cancer; 2004 Aug; 101(3):541-9. PubMed ID: 15274067
[TBL] [Abstract][Full Text] [Related]
9. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
10. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma.
Lee H; McGovern K; Finkelstein JS; Smith MR
Cancer; 2005 Oct; 104(8):1633-7. PubMed ID: 16116596
[TBL] [Abstract][Full Text] [Related]
11. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
Smith MR; McGovern FJ; Zietman AL; Fallon MA; Hayden DL; Schoenfeld DA; Kantoff PW; Finkelstein JS
N Engl J Med; 2001 Sep; 345(13):948-55. PubMed ID: 11575286
[TBL] [Abstract][Full Text] [Related]
12. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
Dhanapal V; Reeves DJ
J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
[TBL] [Abstract][Full Text] [Related]
13. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men.
Alibhai SM; Duong-Hua M; Cheung AM; Sutradhar R; Warde P; Fleshner NE; Paszat L
J Urol; 2010 Sep; 184(3):918-23. PubMed ID: 20643458
[TBL] [Abstract][Full Text] [Related]
14. Fracture risk in androgen deprivation therapy: a Canadian population based analysis.
Lau YK; Lee E; Prior HJ; Lix LM; Metge CJ; Leslie WD
Can J Urol; 2009 Dec; 16(6):4908-14. PubMed ID: 20003666
[TBL] [Abstract][Full Text] [Related]
15. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
[TBL] [Abstract][Full Text] [Related]
16. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.
Smith MR; Fallon MA; Lee H; Finkelstein JS
J Clin Endocrinol Metab; 2004 Aug; 89(8):3841-6. PubMed ID: 15292315
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
18. Bone densitometry as an adjunct to GnRH agonist therapy.
Cann CE
J Reprod Med; 1998 Mar; 43(3 Suppl):321-30. PubMed ID: 9564668
[TBL] [Abstract][Full Text] [Related]
19. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
20. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
Higano CS
Nat Clin Pract Urol; 2008 Jan; 5(1):24-34. PubMed ID: 18185511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
